Oral cannabinoid formulation elevates sensory nerve conduction velocity and mitigates oxidative stress to alleviate neuropathic pain in rats

The vehicle group exhibited significant hyperalgesia (<i>p</i> <0.005), reduced sensory nerve conduction velocity (SNCV) (<i>p</i> <0.005) and elevated MDA and TNF-α levels, along with decreased GSH and CAT levels in both serum and sciatic nerve tissue.Among the formulations, F2 significantly improved pain latency and SNCV (<i>p</i> <0.005) compared to the vehicle group and outperformed F1, F3, F4 and pregabalin (<i>p</i> <0.05). Its effects were mediated through CB1 and CB2 receptor agonism while simultaneously reducing oxidative stress and inflammation, highlighting its potential as a promising candidate for neuropathic pain management.